ArticleFrontiers in pharmacology2017
Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Effect of single parenteral administration of marbofloxacin on bacterial load and selection of resistant Enterobacteriaceae in the fecal microbiota of healthy pigs.BMC veterinary research · 2024Article
- Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models.Frontiers in veterinary science · 2022Review
- Pharmacokinetics and Pharmacodynamics of Colistin Combined With Isopropoxy Benzene Guanidine AgainstFrontiers in microbiology · 2022Article
- Prudent Use of Tylosin for Treatment ofFrontiers in microbiology · 2021Article
- Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.Journal of veterinary science · 2019Review
- Strategic Priorities for Research on Antibiotic Alternatives in Animal Agriculture-Results From an Expert Workshop.Frontiers in veterinary science · 2019Article
- The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin againstOncotarget · 2018Article
- Optimal Regimens and Cutoff Evaluation of Tildipirosin AgainstFrontiers in pharmacology · 2018Article
- PK-PD Integration Modeling and Cutoff Value of Florfenicol againstFrontiers in pharmacology · 2018Article
- Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.Frontiers in pharmacology · 2018Article
- Article
- Comparative Pharmacokinetics and Preliminary Pharmacodynamics Evaluation of Piscidin 1 Against PRV and PEDV in Rats.Frontiers in chemistry · 2018Article
- PK-PD Analysis of Marbofloxacin againstFrontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the activity of marbofloxacin and establish the optimal dose regimens for decreasing the development of fluoroquinolone resistance in pigs against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.